SX-fraction: Promise for novel treatment of type 2 diabetes

doi:10.4239/wjd.v11.i12.572

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 12

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7780)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-3) series.

Item

Count

PDF

432

WORD

245

HTML

3526

Figures (1-6)

1018

Tables (1-3)

572

Sum=5793

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

714

Download

1280

Sum=1994

Dec 15, 2020 (publication date) through Feb 27, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Diabetes. Dec 15, 2020; 11(12): 572-583
Published online Dec 15, 2020. doi: 10.4239/wjd.v11.i12.572

SX-fraction: Promise for novel treatment of type 2 diabetes

Sensuke Konno

Sensuke Konno, Department of Urology, New York Medical College, Valhalla, NY 10595, United States

Author contributions: Konno S contributed to the entire study and manuscript preparation.

Conflict-of-interest statement: Sensuke Konno declares that there is no conflict of interest.

Corresponding author: Sensuke Konno, PhD, Associate Professor, Department of Urology, New York Medical College, BSB Room A03, Valhalla, NY 10595, United States. sensuke_konno@nymc.edu

Received: July 9, 2020
Peer-review started: July 9, 2020
First decision: October 6, 2020
Revised: October 20, 2020
Accepted: November 11, 2020
Article in press: November 11, 2020
Published online: December 15, 2020
Processing time: 156 Days and 11.7 Hours

Core Tip

Core Tip: We have been searching for a natural agent capable of controlling diabetic conditions in patients with type 2 diabetes for years. We then came across “SX-fraction (SXF)”, isolated from maitake mushroom (Grifola frondorsa), with anti-diabetic and hypoglycemic activities. In this short review, we chronologically described several key studies of SXF such as animal studies using diabetic mice (to demonstrate anti-diabetic activity), limited clinical studies on volunteer patients with type 2 diabetes (to show hypoglycemic activity), and in vitro study using skeletal muscle cells (to elucidate the hypoglycemic mechanism). After all, SXF appears to be a natural, safe, effective agent for treatment of patients with type 2 diabetes, although more (clinical) studies are yet required for confirmation.